These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 19943706)

  • 21. [Hepatocellular carcinoma].
    Yamashita T; Arai K; Kaneko S
    Nihon Rinsho; 2010 Oct; 68(10):1861-5. PubMed ID: 20954330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge.
    Kim R; Byrne MT; Tan A; Aucejo F
    Oncology (Williston Park); 2011 Mar; 25(3):283-91, 295. PubMed ID: 21548473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sorafenib use in hepatocellular carcinoma in Japan: early experience and impact on clinical practice.
    Zhu AX
    Clin Drug Investig; 2012 Aug; 32 Suppl 2():1-2. PubMed ID: 22873622
    [No Abstract]   [Full Text] [Related]  

  • 24. Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib.
    Lee JH; Park JY; Kim DY; Ahn SH; Han KH; Seo HJ; Lee JD; Choi HJ
    Liver Int; 2011 Sep; 31(8):1144-9. PubMed ID: 21745288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical analysis of the treatment:transcatheter arterial chemoembolization combined with sorafenib in advanced hepatocellular carcinoma].
    Li Y; Huang JW; Lu LG; Shao PJ; Hu BS; Huang GM; Wei ZG; Zhang L
    Zhonghua Yi Xue Za Zhi; 2010 Aug; 90(31):2187-92. PubMed ID: 21029658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions.
    Welker MW; Lubomierski N; Gog C; Herrmann E; Engels K; Vogl TJ; Bechstein WO; Zeuzem S; Trojan J
    J Chemother; 2010 Jun; 22(3):205-11. PubMed ID: 20566428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.
    Scartozzi M; Faloppi L; Svegliati Baroni G; Loretelli C; Piscaglia F; Iavarone M; Toniutto P; Fava G; De Minicis S; Mandolesi A; Bianconi M; Giampieri R; Granito A; Facchetti F; Bitetto D; Marinelli S; Venerandi L; Vavassori S; Gemini S; D'Errico A; Colombo M; Bolondi L; Bearzi I; Benedetti A; Cascinu S
    Int J Cancer; 2014 Sep; 135(5):1247-56. PubMed ID: 24510746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Developing better treatments in hepatocellular carcinoma.
    Duffy A; Greten T
    Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):551-60. PubMed ID: 20932140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study.
    Zhao JD; Liu J; Ren ZG; Gu K; Zhou ZH; Li WT; Chen Z; Xu ZY; Liu LM; Jiang GL
    Radiat Oncol; 2010 Feb; 5():12. PubMed ID: 20149262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma.
    Zhu AX
    Cancer; 2008 Jan; 112(2):250-9. PubMed ID: 18041064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments.
    Kim HY; Park JW; Nam BH; Kim HK; Choi JI; Kim TH; Kim HB; Kim CM
    J Gastroenterol Hepatol; 2011 Nov; 26(11):1612-8. PubMed ID: 21517968
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sorafenib, a systemic therapy for hepatocellular carcinoma.
    Méndez-Sánchez N; Vásquez-Fernández F; Zamora-Valdés D; Uribe M
    Ann Hepatol; 2008; 7(1):46-51. PubMed ID: 18376365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medical treatments: in association or alone, their roles and their future perspectives: the Western experience.
    Reig M; Bruix J
    J Hepatobiliary Pancreat Sci; 2010 Jul; 17(4):420-1. PubMed ID: 19890601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.
    Kudo M; Ueshima K
    Oncology; 2010 Jul; 78 Suppl 1():154-66. PubMed ID: 20616599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.
    Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Kanai F; Yoshikawa M; Yokosuka O
    Oncology; 2014; 87(6):330-41. PubMed ID: 25227534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Three cases of hepatocellular carcinoma without distant metastasis effectively treated by sorafenib].
    Takeda Y; Nakahira S; Takeno A; Suzuki R; Nakata K; Okishiro M; Egawa C; Okamura S; Miki H; Kato T; Takatsuka Y; Tamura S
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2496-8. PubMed ID: 22202425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical response after sorafenib for hepatocellular carcinoma in elderly patients: a report of two cases.
    Spada F; Squadroni M; Lorizzo K; Farris A; Fazio N
    Tumori; 2012; 98(2):53e-56e. PubMed ID: 22678005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Targeted therapies in hepatocellular carcinoma].
    Bouattour M; Marijon H; Dreyer C; Faivre S; Raymond E
    Presse Med; 2010; 39(7-8):753-64. PubMed ID: 20378303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.
    Huynh H; Choo SP; Toh HC; Tai WM; Chung AY; Chow PK; Ong R; Soo KC
    Curr Cancer Drug Targets; 2011 Oct; 11(8):944-53. PubMed ID: 21834756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference.
    Burak KW; Thomas MB; Zhu AX
    HPB (Oxford); 2010 Jun; 12(5):321-2. PubMed ID: 20590906
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.